Sanofi-Aventis Reportedly In Talks With Nichi-Iko, Could Make Big Splash In Biosimilars
This article was originally published in PharmAsia News
Executive Summary
Toyama-based generics manufacturer Nichi-Iko is reported to be in collaboration talks with Sanofi-Aventis to expand both companies' generic drug business in Japan, including a joint effort to tap into Japan's potential follow-on biologics market
You may also be interested in...
Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan
Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan
Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan
Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan
Merck Eyes Emerging Biosimilars Market In Japan
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012